Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Capital Expenditures (2016 - 2025)

Iovance Biotherapeutics (IOVA) has disclosed Capital Expenditures for 11 consecutive years, with $9.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Capital Expenditures rose 123.61% to $9.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $33.8 million, a 205.68% increase, with the full-year FY2025 number at $33.8 million, up 205.68% from a year prior.
  • Capital Expenditures was $9.3 million for Q4 2025 at Iovance Biotherapeutics, down from $10.8 million in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $10.8 million in Q3 2025 to a low of $442000.0 in Q2 2024.
  • A 3-year average of $5.6 million and a median of $5.2 million in 2024 define the central range for Capital Expenditures.
  • Peak YoY movement for Capital Expenditures: plummeted 94.03% in 2024, then surged 1588.01% in 2025.
  • Iovance Biotherapeutics' Capital Expenditures stood at $3.5 million in 2023, then grew by 18.11% to $4.2 million in 2024, then skyrocketed by 123.61% to $9.3 million in 2025.
  • Per Business Quant, the three most recent readings for IOVA's Capital Expenditures are $9.3 million (Q4 2025), $10.8 million (Q3 2025), and $7.5 million (Q2 2025).